Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 10/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19327367 | 0.84 | HTR1B (0.71) | RELAHTR1B | |
| SCHEMBL19327366 | 0.84 | HTR1B (0.71) | RELAHTR1B | |
| SCHEMBL19327354 | 0.81 | NFE2L2 (0.58) | NFE2L2RELAAPP | |
| SCHEMBL19327353 | 0.81 | NFE2L2 (0.58) | NFE2L2RELAAPP | |
| SCHEMBL16809146 | 0.76 | HTR1B (0.66) | HTR1B | |
| SCHEMBL14401253 | 0.75 | NFE2L2 (1.00) | NFE2L2RELAAPPPTGS1 | |
| SCHEMBL30756752 | 0.75 | HTR1B (0.61) | HTR1B | |
| SCHEMBL13272286 | 0.75 | HTR1B (0.61) | HTR1B | |
| SCHEMBL5490778 | 0.75 | NFE2L2 (1.00) | NFE2L2RELAAPPPTGS1 | |
| SCHEMBL5490783 | 0.75 | NFE2L2 (1.00) | NFE2L2RELAAPPPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260126-A1 | SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION | UNIV OXFORD INNOVATION LTD (GB) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260126-A1 | SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION | LDLR, NR1H2, SREBF1 | NFE2L2 777/4885RELA 312/4885HTR1B 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.